item management s discussion and analysis of financial condition and results of operations overview urologix  inc  incorporated in  develops  manufactures and markets minimally invasive medical devices for the treatment of urological diseases 
the company has developed the targis system  a non surgical  anesthesia free  catheter based therapy that uses a proprietary microwave technology for the treatment of benign prostatic hyperplasia bph  a disease that affects over million men worldwide 
in august  the company received food and drug administration fda approval to market the targis system in the united states and launched the targis system in the united states during the fourth calendar quarter of regulatory approvals necessary to market the targis system in japan and the european union countries were obtained in fiscal year the company s targis system consists of a control unit and a procedure kit  which includes the microwave delivery system incorporated in a catheter  a cooling bag and a rectal thermosensing unit 
the company markets the targis system through a direct sales force in the united states 
internationally  the company has developed broad based relationships with two parties for market development and sales of the targis system 
boston scientific corporation  a worldwide developer  manufacturer and marketer of medical devices  has exclusive distribution rights for the targis system in all countries outside the united states  except japan 
nihon kohden corporation  a major japanese developer  manufacturer and marketer of medical devices  has exclusive distribution rights for the targis system in japan 
since inception  the company has experienced operating losses and anticipates that its operating losses will continue for the foreseeable future 
expenditures will be primarily related to the continuing targis system market introduction in the united states  scale up of commercial manufacturing  clinical trials and research and development activities 
the company expects sales of the targis system to account for all of its revenues for the foreseeable future 
in the united states  the company offers urologists or hospitals the option to purchase or lease the targis system control unit 
the leases are offered by a third party lessor directly to the company s customer  allowing the company to record the transaction as a sale 
revenues from the sale of targis system control units and disposable procedure kits are recognized upon shipment 
results of operations fiscal years ended june  and sales increased to million in fiscal year from million in fiscal year due to initial sales in the united states resulting from fda commercial marketing approval and an increase in shipments of the targis system to the company s international distributors resulting from regulatory marketing approvals obtained in the european union and japan 
sales in the united states represented approximately of total sales in fiscal year the company expects to continue increasing united states sales of the targis system in fiscal year  however  international sales are expected to be minimal due to significant inventory levels of the targis system at the company s international distributors 
cost of goods sold includes raw materials  labor and royalties  as well as costs incurred in connection with the production of targis systems 
cost of goods sold increased to million in fiscal year from million in fiscal year  due primarily to the significant increase in sales and production 
cost of goods sold were impacted by two events in first  the company wrote down finished goods inventory by  during the third quarter as a result of a component that caused an occasional failure of the targis system catheters 
second  during the fourth quarter  the company reduced its current production schedule in anticipation of introducing an upgraded catheter in fiscal year  resulting in the allocation of overhead over a lower production volume 
the upgraded catheter production began in july the company expects costs of goods sold as a percentage of sales to decrease in due to higher united states sales as a percentage of total sales and efficiencies obtained from higher production volumes 
research and development expenses include those costs associated with the development and protection of the company s intellectual property  treatment of patients participating in clinical trials  the accumulation of outcome data to substantiate clinical results and the preparation and submission of applications for regulatory approvals 
research and development expenses in fiscal year increased to million from million in fiscal year primarily due to costs related to new and on going clinical studies of the targis system  product development activities related to targis system improvements and alternative applications for the company s technology  and the company s settlement of litigation concerning its rights under a previous settlement agreement see note of notes to financial statements 
research and development expenses in fiscal year are expected to decrease due to the conclusion of some clinical studies  lower regulatory expenses and the recent settlement of litigation 
sales and marketing expenses in fiscal year increased to million from million in fiscal year  due primarily to costs associated with the company s us marketing launch of the targis system and supporting the marketing of the targis system in europe and japan 
these costs included the hiring of sales and marketing management  preparation of promotional materials  recruitment of field sales representatives and efforts related to obtaining third party reimbursement for the targis system 
the company expects sales and marketing expenses to increase as it increases its sales efforts in the united states  including the expected expansion of its direct sales force  and continues supporting its international distributors sales efforts 
general and administrative expenses in fiscal year increased slightly to million from million in fiscal year due to administrative costs associated with an increase in employees in connection with the company s growth and commencement of united states sales activities 
interest income was relatively unchanged for year compared to fiscal year  primarily as a result of similar average invested balances 
litigation settlement expenses resulted from the settlement agreement described above 
fiscal years ended june  and sales increased to million in fiscal year from  in fiscal year due to sales of the targis system to the company s international distributors as a result of marketing approvals obtained during fiscal in the european union and japan 
costs of goods sold increased to million in fiscal year from million in fiscal year  primarily due to the increase in sales of the targis system 
research and development expenses increased to million in fiscal year from million in fiscal year due primarily to costs associated with the filing of the targis system pre market approval application pma with the fda and clinical studies conducted to document the safety and efficacy of the targis system 
sales and marketing expenses increased to million in fiscal year from million in fiscal year  primarily due to costs associated with the marketing launch of the targis system in europe and japan and preparation for united states marketing launch 
preparations included the hiring of sales and marketing management  preparation of promotional materials  recruiting for field sales representatives and efforts related to obtaining medical reimbursement for the targis system 
general and administrative expenses increased to million in fiscal year from million in fiscal year due to administrative costs associated with an increase in employees in connection with the company s growth and commencement of sales activities  and costs related to the company s external reporting obligations as a public company 
interest income increased significantly during fiscal year  due primarily to income from the investment of proceeds from the company s initial public offering  completed in june liquidity and capital resources the company has financed its operations since inception through sales of equity securities and  to a lesser extent  sales of the targis system 
as of june   the company had total cash  cash equivalents and available for sale securities of million and working capital of million 
during fiscal year  the company used million in operating activities  primarily reflecting the company s net loss  an increase in inventories of million and an increase in accounts receivable of million 
the company used million in investing activities  primarily reflecting the net purchase of million in securities  million for the purchase of property and equipment and million for the purchase of other assets 
the company financed its fiscal year operating and investing activities primarily through a november secondary offering that raised net proceeds of million 
at june   the company had committed to purchase million in components for the targis systems from a third party vendor see note to notes to financial statements 
the company expects to continue to incur additional losses  and will use its working capital as it incurs substantial expenses related to the targis system market introduction in the united states  clinical trials and research and development activities 
in addition  should the company choose to rent targis system control units to customers in the future  substantial capital could be required 
although the company believes that existing cash  cash equivalents and available for sale securities will be sufficient to fund its operations for at least the next months  there can be no assurance that the company will not require additional financing in the future or that any additional financing will be available to the company on satisfactory terms  if at all 
year issue the company is evaluating the potential impact of what is commonly referred to as the year issue  concerning the inability of certain information systems to properly recognize and process dates containing the year and beyond 
the company has established a dedicated year team working with every operational area throughout the company  and this team has worked with management to commence the following steps i implementing a year assessment and testing plan for all internal information systems and other systems that contain microcontrollers that may be affected by the year date change  ii implementing a year assessment and testing plan for all company products  iii communicating with third parties that supply product to the company to ensure they are addressing the year issue  and iv contingency and disaster recovery planning to ensure year problem resolution 
the company has identified and tested the systems it believes are mission critical  and the test results indicate that these systems are year compliant 
the company expects to complete testing and establish compliance with respect to all of its systems and products by december   subject to possible equipment upgrades during and ongoing communications with third parties 
regardless of the year compliance of the company s systems and products  there can be no assurance that the company will not be adversely affected by the failure of others to become year compliant 
the company estimates that its direct costs for year compliance will consist of costs related to the staff time devoted to year compliance 
the company does not expect capital expenditures will be necessary related to year compliance 
costs and capital expenditures in these areas have not been material for historical periods 
as noted below under forward looking statements  statements in this section that are not historical or current facts are forward looking statements made pursuant to the safe harbor provisions of the private securities litigation reform act of  including statements regarding the timetable for year compliance  the company s costs and capital expenditures  the success of the company s efforts and others efforts to achieve compliance  and the effects of the year issue on the company s future financial condition and results of operations 
these statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results and those presently anticipated or projected 
the following important factors  among others  could affect the accuracy of these statements i the inherent uncertainty of the costs and timing of achieving compliance on the wide variety of systems used by the company  ii the reliance on the efforts of vendors  customers  government agencies and other third parties to achieve adequate compliance and avoid disruption of the company s business in early and iii the uncertainty of the ultimate costs and consequences of any unanticipated disruption in the company s business resulting from the failure of one of the company s applications or of a third party s systems 
the foregoing list is not exhaustive  and the company disclaims any obligation subsequently to revise any forward looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events 
forward looking statements statements included in this report that are not historical or current facts are forward looking statements made pursuant to the safe harbor provisions of the private securities litigation reform act of and are subject to certain risks and uncertainties that could cause actual results to differ materially 
these risks and uncertainties include competition from other bph treatments  the ability of the company s distributors and representatives to successfully market and sell the targis system  the company s ability to manufacture the targis systems in sufficient quantities  the company s ability to maintain intellectual property protection for its proprietary products and to defend its existing intellectual property rights from challenges by third parties  and the extent to which the physicians performing the targis system procedures are able to obtain third party reimbursement 
in addition  a detailed discussion of risks and uncertainties may be found in the section entitled business forward looking statements in this form k 

